GlassScriptPhysician profile
Alison S Stevons
NPI 1073553160
$3,157.47
in general payments reported to CMS, 2019-2025
15 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $294 · 2023: $668 · 2024: $932 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,745.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,525.43 | 2023-2025 | |
| Janssen Biotech, INC. | $474.11 | 2023-2025 | Stelara, Tremfya |
| Pfizer INC. | $370.81 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.44 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $167.44 | 2021-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $130.22 | 2022-2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $76.30 | 2021-2023 | Rebyota |
| Celgene Corporation | $43.86 | 2022 | |
| Phathom Pharmaceuticals, INC. | $42.70 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $34.37 | 2023-2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $33.18 | 2023 | Dupixent |
| Evoke Pharma, INC. | $23.88 | 2022 | |
| Celltrion USA INC. | $23.42 | 2025 | Vegzelma |
| Genzyme Corporation | $21.82 | 2022 | |
| Sandoz INC. | $19.49 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Stevons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.